TAS-102

DB08937InvestigationalSmall molecule

TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase... It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine.

Mechanism: Pharmacologically active on Thymidylate synthase and Thymidine phosphorylase
Curator reviewed
Code names: TAS-102

Resolves to

Compound

CAS733030-01-8

Targets

P04818TYMSP19971TYMP

What you can answer from here — as of July 03, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with TAS-102, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account